New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:28 EDTDHR, DGX, RHHBY, ABT, JNJ, LHCLFS review potential negative for Quest, LabCorp, says Piper Jaffray
Piper Jaffray views the Centers for Medicare & Medicaid Services' plan to revalue Clinical Lab Fee Schedule test codes as a potential negative for Quest Diagnostics (DGX) and LabCorp (LH) as well as diagnostic manufacturers like Abbott (ABT), Danaher (DHR), Johnson & Johnson (JNJ) and Roche (RHHBY). Piper says Quest and LabCorp both have around 12% of revenue exposure to CLFS, which it feels presents risk for additional reimbursement pressure in FY15. The review follows an Office of Inspector General report that found CMS paid between 18%-30% higher for 20 high volume/high expenditure tests than state and federal plans.
News For DGX;LH;ABT;DHR;JNJ;RHHBY From The Last 14 Days
Check below for free stories on DGX;LH;ABT;DHR;JNJ;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 16, 2014
11:23 EDTDHRDanaher says "very busy" on M&A front
says "very, very busy" on M&A side. Sees ability to get deals done. Says July, August, "a little better than we thought" in U.S., Europe "okay." Says has a "little bit" of exposure to Russia, "hurting us a little bit" right now. Comments made at the Morgan Stanley Laguna Conference.
08:04 EDTLHLabCorp, ARCA Biopharma present GENETIC-AF poster at HFSoA meeting
Subscribe for More Information
07:31 EDTRHHBY, JNJEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
09:32 EDTABTAbbott initiates ABSORB IV trial
Abbott announced the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold is more cost-effective and offers a higher quality of life than a permanent, metallic drug eluting stent. Unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3K people with coronary artery disease, mostly in the U.S. The ABSORB IV trial is designed to confirm these novel findings that treatment with the Absorb device can help provide people with heart disease a higher quality of life after a heart stent procedure. The data from the ABSORB IV trial will be combined with the data from the ABSORB III trial to create a population of more than 5K people studied in the U.S. This data set, which is the largest of its kind for bioresorbable heart devices, provides an opportunity to evaluate the performance of Absorb compared to the current standard of a metallic drug eluting stent across a number of measures, including the broader health economic impact of this innovative therapy.
08:56 EDTDHRDanaher: It's important not to read too much into 2 deals for company direction
Subscribe for More Information
08:49 EDTDHRDanaher expects global dentistry market to grow 3%-5%
Subscribe for More Information
08:47 EDTDHRDanaher expects Nobel Biocare acquisition to be accretive to EPS by 5c in 2015
Subscribe for More Information
07:45 EDTABTCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:42 EDTDHRMorgan Stanley to hold a conference
Subscribe for More Information
07:27 EDTJNJIBC Life Sciences to hold a conference
Subscribe for More Information
07:21 EDTLHHeart Failure Society of America to hold annual meeting
Subscribe for More Information
05:58 EDTDHRDanaher to host conference call
Subscribe for More Information
05:20 EDTDHRDanaher to acquire Nobel Biocare Holding for CHF 17.10 per share
Danaher has entered into a definitive transaction agreement with Nobel Biocare Holding AG pursuant to which Danaher or one of its direct or indirect subsidiaries will commence a tender offer for all publicly held registered shares of Nobel Biocare in an all-cash transaction valued at approximately $2.2B. The deal is expected to widen Danaher's market presence in the global dental industry and allow Nobel Biocare to accelerate its strategic objectives and future growth. Under the terms of the transaction agreement, Danaher will commence a voluntary all-cash public tender offer of CHF 17.10 per Nobel Biocare share to purchase all of Nobel Biocare's publicly held registered shares. The pre-announcement of the public tender offer is published today. The offer prospectus is expected to be published on or around October 1 and the offer period during which Nobel Biocare shareholders may tender their registered shares is expected to start on or around October 16. In 2013, Nobel Biocare generated annual revenues of approximately $750M. Nobel Biocare would become part of Danaher's $2.2B Dental segment and complements Danaher's position in the implant industry. The Nobel Biocare board has recommended that Nobel Biocare shareholders accept and tender their shares into the offer, which represents a premium of approximately 23% to Nobel Biocare's closing price on July 28, the day before market speculation began regarding a potential sale of the company, or 28% on the basis of the 60 day volume-weighted average price on that date. The offer is expected to be completed in late 2014 or early 2015.
05:17 EDTDHRDanaher to acquire Nobel Biocare Holding for CHF 17.10 per share
Subscribe for More Information
September 14, 2014
13:30 EDTABTAbbott announces positive one-year clinical results from ABSORB II
Subscribe for More Information
September 11, 2014
13:41 EDTABTAbbott announces new $3B share repurchase program
Subscribe for More Information
07:11 EDTJNJMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
September 10, 2014
13:04 EDTRHHBYRoche unit receives orphan status for lung cancer mutation drug
Subscribe for More Information
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information
September 9, 2014
06:42 EDTABTLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use